NCT05899621 A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
| NCT ID | NCT05899621 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ruijin Hospital |
| Condition | Follicular Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 332 participants |
| Start Date | 2023-06-01 |
| Primary Completion | 2025-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 332 participants in total. It began in 2023-06-01 with a primary completion date of 2025-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to observe and explore the efficacy and safety of obinutuzumab-based therapy for previously untreated follicular lymphoma
Eligibility Criteria
Inclusion Criteria: * Pathologically confirmed CD20 positive follicular lymphoma grade 1, 2, or 3A based on 2016 WHO classification * Treatment naive * Age ≥ 18 years * Indications for treatment confirmed * Must has measurable lesion in CT or PET-CT prior to treatment * Considered suitable for GR, GB or GCHOP regimens * Informed consented Exclusion Criteria: * Transformed follicular lymphoma or 3B follicular lymphoma; * HBsAg positive and / or HBcAb positive with HBV DNA titer; HCV antibody positive with HCV-RNA; or HIV positive * Central nervous system or meninges involved * Any drug contraindication in the treatment plan * Patients judged by other researchers to be unsuitable for inclusion in the study
Contact & Investigator
Weili Zhao
STUDY CHAIR
Ruijin Hospital
Frequently Asked Questions
Who can join the NCT05899621 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Follicular Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05899621 currently recruiting?
Yes, NCT05899621 is actively recruiting participants. Contact the research team at zwl_trial@163.com for enrollment information.
Where is the NCT05899621 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT05899621 clinical trial?
NCT05899621 is sponsored by Ruijin Hospital. The principal investigator is Weili Zhao at Ruijin Hospital. The trial plans to enroll 332 participants.